0:22 Meeting Introduction and Committee Member Introductions 1:31 Overview of 503A Bulk Drug Substances and Evaluation Process 6:09 Conflict of Interest Statements and Committee Roles 12:30 FDA Overview of Compounding Regulations and 503A Evaluation Criteria 21:25 Discussion on Regulatory Implications of Compounded Drug Products 27:11 Challenges with Conflated Bulk Drug Substances and Regulatory Definitions 36:28 The Problem of Common and Company Names in Experimental Substances and Compounding 37:57 Identity and Characterization Challenges of Experimental Substances in Compounding 39:48 The Critical Need for Defining Substance Identity Before Quality and Safety Assessment 42:53 The Dilemma of Voting on Substances Without Clear Identity or Regulatory Authority 44:13 Clarifying Questions on the Nomination Process and the Role of the Committee 45:46 The Complexity of Characterizing Peptides and the Limitations of Current Data 48:59 The Challenge of Establishing Regulatory Authority and Standardization for Peptide Substances 51:16 The Gap in Safety Data and Oversight for Compounded Peptides in the Gray Market 52:21 The Process of Nominating Substances and the Limitations of Current Application Requirements 53:50 The Role of the Committee in Evaluating Substances and the Implications of Adding to the Bulk List 55:57 The Impact of Non-Standardized Use on Future Drug Development and Regulatory Approval 58:43 The Need for Monographs and Standardization to Address Characterization and Safety Issues 1:02:38 The Open Public Hearing Session and the Importance of Transparency and Financial Disclosure 1:05:14 Public Advocacy Against Adding Emideltide to the 503A Bulk Drug Substance List 1:10:17 Evaluation of Emideltide Evidence and Safety Concerns 1:11:55 Public Citizen's Position on Emideltide and the 503A Bulk List 1:12:05 Personal Testimony on Peptide Use and Access Challenges 1:12:58 Advocacy for Evidence-Based Medicine and Patient Safety 1:14:34 Industry Perspective on Compounding and Regulatory Pathways 1:16:57 Support for Regulated Compounding and API Development 1:18:43 Case for Compounding Peptides with Safeguards and Oversight 1:20:50 Industry and Clinical Support for Peptide Access and Regulation 1:22:01 Clinical Experience and Safety Data on Peptides 1:23:57 Advocacy for Traceability and Quality Control in Compounding 1:25:01 Technical and Manufacturing Considerations for Peptide Characterization 1:26:34 Call for Accountability and Oversight in Peptide Supply Chains 1:27:09 Scientific Background and Mechanism of Action of Emideltide 1:28:04 Clinical Applications and Patient Case Examples 1:29:57 Personal Experience and Recommendation for Peptide Use 1:31:09 Advocacy for Restoring Access to Peptides via 503A Pathway 1:34:12 Comparison of Current Therapies and Risks of Sleep and Opioid Withdrawal Treatments 1:35:12 Advocacy for Regulatory Restoration of DSIP and Peptide Therapeutics in 503A Compounding 1:37:02 Scientific and Regulatory Framework for DSIP Characterization and Quality Control 1:38:50 Personal and Professional Perspective on Evidence, Policy, and Public Health Responsibility 1:40:42 Historical and Clinical Evidence for DSIP and the Need for a Balanced Regulatory Approach 1:42:56 Regulatory and Manufacturing Standards for Peptide Compounding and the Role of 503A 1:45:13 Real-World Safety Data and the Case for Physician-Guided Peptide Therapy 1:47:40 Clinical Experience and the Ethical Imperative for Access to Peptide Therapeutics 1:50:59 Patient Advocacy and the Call for Regulated Access to Peptides to Replace the Black Market 1:55:53 FDA Presentation on Imideltide-Related Bulk Drug Substances and Regulatory Evaluation 1:58:09 Overview of Imideltide Nominations and FDA Evaluation Criteria 2:02:18 Physical and Chemical Characterization of Imideltide Freebase and Acetate 2:06:36 Pharmacological and Mechanistic Properties of Imideltide 2:10:08 Evidence of Effectiveness for Chronic Insomnia 2:16:00 Evidence of Effectiveness for Narcolepsy 2:18:33 Evidence of Effectiveness for Opioid Withdrawal 2:22:28 Safety Considerations for Imideltide 2:26:09 Transition to Next Presenter 2:26:10 Overview of Amydeltide-Related Bulk Drug Substances in Compounding 2:27:53 Regulatory and Pharmacopoeial Status of Amydeltide-Free Base and Amydeltide Acetate 2:28:49 FDA's Conclusion on Inclusion in the 503A Bulks List 2:29:41 Presentation Conclusion and Transition to Committee Questions 2:30:33 Committee Member Dr. Wusterhausen's Questions and Comments on Public Comments and FDA Review Process 2:31:57 Clarification on FDA's Review of Public Comments and Information Submitted After Evaluation 2:33:38 Response to Questions on FDA's Evaluation Process and Public Docket 2:35:20 Discussion on the Implications of the 503A Bulks List and Legal Access for Compounding 2:36:36 Clarification on the Use of Criminal Prosecution Information in the Presentation 2:38:42 Transition to Dr. Zakharoff's Questions 2:38:48 Questions on Withdrawn Nominations and FDA's Discretion to Evaluate Substances 2:40:23 Clarification on the Meaning of "Addiction" and Related Behavioral Assessments 2:42:04 Inquiry on Precedent for Reduced Availability After Inclusion on the 503A Bulks List 2:46:20 Transition to Dr. Levski's Questions 2:46:24 Clarification on the Role of Effectiveness Evidence in 503A Compounding Decisions 2:47:30 Response to Questions on Safety Data and Non-Clinical Requirements for DSIP 2:48:25 Follow-Up on Safety Data and Further Requirements for FDA Evaluation 2:49:48 Evaluation of Safety and Efficacy Data for Dauteron and Imideltide 2:51:27 Solubility and Formulation Challenges for Imideltide 2:53:26 Pharmacological Activity and EEG Study Inconsistencies 2:55:17 Clinical Study Regimen and Public Use Concerns 2:57:27 Regulatory and Safety Considerations for Compounding 2:59:02 Criteria for Selecting Peptides for the 503A Bulk List 3:02:32 Challenges in Establishing USP Monographs for Novel Peptides 3:05:53 Final Voting and Rationale on Inclusion of Emidel and Mldeltide on the 503A List 3:18:22 Vote on USP and Epitalon-related bulk drug substances 3:32:00 Opening remarks and introduction of Epitalon evaluation 3:33:58 Public hearing: Dr. Jeffrey Eggler on Epitalon's clinical potential and safety 3:36:15 Public hearing: Dr. John Herdig on safety concerns and regulatory challenges 3:39:26 Public hearing: Dr. Omar Baker on conditional access and quality control 3:42:19 Public hearing: Dr. Josh Sweeter on analytical characterization and quality issues 3:46:11 Public hearing: Dr. Matt Cooke on clinical use and safety profile 3:49:55 Public hearing: Dr. Alex Tatum on clinical lineage, mechanism, and real-world evidence 3:53:49 Public hearing: Dr. Jim Lovell on characterization, quality standards, and real-world data 3:56:28 Critique of Inadequate Testing and Certificate of Analysis 3:57:00 Governor Ricardo Rosselló: Advocacy for Epitalin with Policy and Scientific Perspective 3:59:59 Lee Rosemush: Defense of Compounding Access and Critique of FDA's Use of Incomplete Data 4:04:44 Conclusion of Public Hearing and Transition to FDA Presentations 4:05:23 FDA Presentation: Physical and Chemical Characterization of Epitalon-Related Bulk Drug Substances 4:16:57 FDA Presentation: Effectiveness and Safety Evaluation of Epitalon 4:26:12 FDA Presentation: Historical Use in Compounding and Final Conclusion 4:29:08 FDA Clarification on Real-World Evidence and Safety Assessment 4:31:54 Panel Questions for FDA Presenters 4:32:23 Clarification on Epitalon Review and Public Forum Comments 4:35:24 Discussion on FDA Evaluation of Epitalon Uses and Scientific Evidence 4:39:04 Questions on Epitalon Registration and Chemical Characterization 4:42:52 Concerns Regarding Impurity Profile and Carcinogenicity Signal 4:47:48 Voting on Epitalon-3bis and Rationale from Panel Members 4:50:01 Voting on Epitalon Acetate and Panel Member Rationale 4:58:06 Adjournment for Lunch and Introduction to Semex-Related Substances 6:04:47 Open Public Hearing on Semex-Related Bad Drug Substances and CMAX 6:15:01 Final Comments on Safety and Evidence Base for CMAX 6:15:50 Elysium Health's Position on CMAX: Safety, Quality, and Regulatory Concerns 6:16:59 Personal and Professional Testimony on CMAX and the Role of the FDA 6:19:37 Clinical Experience and Efficacy of CMAX in Practice 6:23:38 Scientific and Clinical Evidence for CMAX: Mechanism, Safety, and Real-World Use 6:28:03 Technical and Regulatory Framework for CMAX Compounding and Quality Control 6:31:33 Advocacy for Supervised Access and Structured Framework for CMAX 6:35:45 Comprehensive Evidence and Safety Data for CMAX from International and Real-World Use 6:40:13 Physician Perspective on Patient Demand and the Risks of Unregulated Access 6:43:23 Closing Remarks and End of Public Hearing Session 6:44:17 Introduction to FDA Presentations on CMAX-Related Bulk Drug Substances 6:45:23 Evaluation of CMAX-Related Bulk Drug Substances: Nomenclature, Forms, and Initial Assessment 6:47:03 Physical and Chemical Characterization of CMAX Freebase and CMAX Acetate 6:51:02 Critical Quality Attributes and Safety Concerns for CMAX-Related Dosage Forms 6:56:32 Conclusion on Physical and Chemical Characterization of CMAX-Related Substances 6:58:37 Effectiveness and Safety Assessment of CMAX-Related Bulk Drug Substances for Cerebral Ischemia, Migraine, and Trigeminal Neuralgia 7:12:36 Historical Use and Compounding of CMAX-Related Substances 7:18:34 Overview of CMEX-Related Conditions and Online Product Availability 7:19:51 FDA Evaluation of CMEX Freebase and CMEX Acetate for 503A Bulk List Inclusion 7:20:43 FDA's Conclusion on CMEX Substances and Rationale for Exclusion 7:21:12 Presentation Closing and Transition to Panel Q&A 7:21:50 Panel Q&A Introduction and Guidelines 7:22:37 Clarifying Questions on FDA's Data and FAERS Reporting 7:23:33 Discussion on Russian-Language Literature and Study Limitations 7:24:44 Questions on Clinical Use, Therapeutic Window, and Safety Concerns 7:25:53 Clarification on Compounding History and Regulatory Implications 7:27:04 Discussion on Indications and Clinical Relevance of CMEX 7:28:07 Questions on Study Design, Placebo Effect, and Clinical Translation 7:29:54 Clarification on Cerebral Ischemia Indications and Study Parameters 7:30:10 Follow-Up on Study Design, Placebo Effect, and Clinical Relevance 7:31:56 Questions on Therapeutic Window and Safety with TPA 7:33:24 Clarification on Time of Administration and Co-Administration Risks 7:34:40 Discussion on Nominator Communication and Information Gaps 7:35:08 Questions on Nominator Process and Completeness of Submissions 7:36:24 Clarification on Nominator Engagement and Information Requests 7:37:40 Emphasis on Completeness of Nomination Submissions 7:38:59 Final Questions on Stability and Storage Conditions 7:39:06 Discussion on Stability, Storage, and Compounding Feasibility of CMEX Substances 7:43:06 USP Concerns About Name Confusion with Semoxinib and the Importance of Use and Process Naming 7:44:52 Voting Process and Initial Vote on Semex Freebase for 503A Box List 7:46:40 Panelist Statements on Semex Freebase Vote and Rationale 7:50:46 Panelist Statements on Semex Acetate Vote and Rationale 7:58:39 Closing Remarks, Thank Yous, and Adjournment of the Meeting
AI Generated · May contain errors